Atlas Venture Funds Disclose $46.9M in Recent Share Sales
DYN has more than doubled off its 52-week low of $8.06.
Summary
Atlas Venture funds have reported selling $46.9 million worth of Dyne Therapeutics stock over the last three months, signaling significant distribution by a key institutional investor.
Key Events · Ownership and Investor Activity · DYN
-
Significant Institutional Selling
Atlas Venture funds sold approximately $46.9 million in common stock between April 20 and June 26, 2026. This represents about 1.3% of the company's market capitalization.
-
Ongoing Distribution Pattern
This follows a broader trend of insider distribution, with net sales of over $51 million reported by insiders in the last 90 days, aligning with the disclosed sales by Atlas Venture.
-
Intent to Sell Additional Shares
Atlas Venture Opportunity Fund I, LP also filed an intent to sell an additional 40,702 shares, valued at approximately $852,299.88, on June 29, 2026.
Analysis · DYN · Life Sciences
Atlas Venture funds, a significant institutional shareholder, have disclosed cumulative sales of approximately $46.9 million in Dyne Therapeutics common stock over the past three months. This substantial selling activity by a major investor, representing over 1.3% of the company's market capitalization, could indicate a shift in their investment thesis or a move to rebalance their portfolio, potentially creating an overhang on the stock.
How filings like this one have moved
In the 30 days to Sep 21, 2026, 29.2% of the 1541 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DYN was trading at $21.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.5B. The 52-week trading range was $8.06 to $25.00. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.